Phase II Trial of CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

• Status: Not yet recruiting
• Trial end date: 2030-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder.

The CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baptist Health South Florida
• Treatments: Busulfan; Fludarabine; Melphalan

Criteria

Inclusion Criteria:

• Myelodysplastic syndrome (MDS): RA/RARS/RCMA with high-risk cytogenetic features or transfusion dependence, as well as RAEB-1 and RAEB-2

• Karnofsky (adult) Performance Status of at least 70%

• Adequate organ function measured by:

• Cardiac: asymptomatic or if symptomatic then LVEF at rest must be 50% and must improve with exercise.

• Hepatic: < 3x ULN AST and: s 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant (e.g. AML Chloroma obstructing the biliary tree). Patients with higher bilirubin levels due to causes other than active liver disease is also eligible with Pl approval e.g. patients with PNH, Gilbert's disease or other hemolytic disorders.

• Renal: serum creatinine:. s; <1.2 mg/dli (normal range 0.7-1.3) or if serum creatinine is outside the normal range, then CrCl > 5940 ml/m in (measured or calculated/estimated).

• Pulmonary: asymptomatic or if symptomatic, DLCO 50% of predicted (corrected for hemoglobin).

• Willing to participate and must sign an informed consent form

Exclusion Criteria:

• Pregnant or breast-feeding

• Active viral, bacterial or fungal infection

• Patient seropositive for HI V-I /II; HTLV -I /II

• Presence of leukemia in the CNS